Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ez-PAVE: Ezetimibe Combination Therapy LDL Target <70 vs <55 mg/dL in ASCVD
KCT0005547Phase 4Completed
- Sponsor
- Yuhan
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ezetimibe in atherosclerotic disease, coronary arteriosclerosis, sponsored by Yuhan. Started Jan 2021; status: completed.
02
Drugs
ezetimibe
03
Conditions
atherosclerotic diseasecoronary arteriosclerosis
Beyond the preview
Go deeper on KCT0005547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005547.